Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  DBV Technologies    DBV   FR0010417345

DBV TECHNOLOGIES

(DBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
17.39(c) 17.37(c) 17.95(c) 17.6(c) 17.63(c) Last
82 539 106 169 230 395 103 731 125 724 Volume
-0.06% -0.12% +3.34% -1.95% +0.17% Change
More quotes
Financials (EUR)
Sales 2019 14,7 M
EBIT 2019 -161 M
Net income 2019 -175 M
Finance 2019 149 M
Yield 2019 -
Sales 2020 18,6 M
EBIT 2020 -155 M
Net income 2020 -151 M
Finance 2020 64,9 M
Yield 2020 -
P/E ratio 2019 -4,53x
P/E ratio 2020 -5,39x
EV / Sales2019 55,5x
EV / Sales2020 48,2x
Capitalization 962 M
More Financials
Company
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin. 
Sector
Pharmaceuticals
Calendar
02/26 | 01:00pmPresentation
More about the company
Surperformance© ratings of DBV Technologies
Trading Rating : Investor Rating :
More Ratings
Latest news on DBV TECHNOLOGIES
02/21DBV TECHNOLOGIES : Stabilization Notice
PU
02/21DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin P..
GL
02/21DBV TECHNOLOGIES : Announces FDA Advisory Committee Meeting to Review Viaskin Pe..
GL
02/14DBV TECHNOLOGIES : Stabilization Notice
PU
02/14DBV TECHNOLOGIES : Report
CO
02/10DBV TECHNOLOGIES : to Present at the SVB Leerink 9th Annual Global Healthcare Co..
GL
02/06DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical O..
GL
02/06DBV TECHNOLOGIES : Nomination
CO
02/04DBV Technologies Announces Closing of Global Offering
GL
02/04DBV TECHNOLOGIES : Monthly statement on outstanding equity shares and voting rig..
CO
01/31DBV TECHNOLOGIES : Announces Pricing of $153.7 million Global Offering of Ordina..
AQ
01/30DBV TECHNOLOGIES : Announces the Launch of a Proposed Global Offering of Ordinar..
AQ
01/30DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global ..
GL
01/29DBV Technologies Announces the Launch of a Proposed Global Offering of Ordina..
GL
01/15DBV TECHNOLOGIES : Half-Year Report on the DBV Technologies Liquidity Contract w..
GL
More news
News in other languages on DBV TECHNOLOGIES
02/21DBV TECHNOLOGIES : le Comité Consultatif de la FDA se réunit le 15 mai
02/21DBV TECHNOLOGIES : Avis de Stabilisation
02/21DBV TECHNOLOGIES : annonce la tenue de la réunion du Comité Consultatif de la FD..
02/14DBV TECHNOLOGIES : Avis de Stabilisation
02/11DBV TECHNOLOGIES : Morgan Stanley passe sous les 5%
More news
Analyst Recommendations on DBV TECHNOLOGIES
More recommendations
Sector news : Diagnostic & Testing Substances Manufacturers
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Diagnostic & Testing Substances Manufacturers
Chart DBV TECHNOLOGIES
Duration : Period :
DBV Technologies Technical Analysis Chart | DBV | FR0010417345 | MarketScreener
Technical analysis trends DBV TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 33,33  €
Last Close Price 17,63  €
Spread / Highest target 187%
Spread / Average Target 89,1%
Spread / Lowest Target 32,7%
EPS Revisions
Managers
NameTitle
Daniel Tassé Chief Executive Officer & Executive Director
Michel de Rosen Non-Executive Chairman
Ramzi Benamar Chief Financial Officer
Bertrand Dupont Chief Technology Officer
Hugh A. Sampson Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
DBV TECHNOLOGIES-10.19%1 045
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679